Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults

A phase IV, randomized, open-label, controlled study

Patricia Izurieta, Woo Joo Kim, Seong Heon Wie, Jacob Lee, Jin Soo Lee, Mamadou Dramé, David W. Vaughn, Anne Schuind

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: AS03-adjuvanted H5N1 pandemic influenza vaccines have been assessed in an extensive clinical development program conducted in North America, Europe, and Asia including children from 6 months of age, adults, and elderly adults. We evaluated AS03-H5N1 in Korean adults 18 through 60 years of age. Methods: This Phase IV, randomized, study was conducted to assess the immunogenicity, reactogenicity, and safety of two doses (3.75. μg of hemagglutinin antigen) of A/Indonesia/5/2005 (H5N1) adjuvanted with AS03 given 21 days apart in Korean adults. Antibody responses were assessed using hemagglutination-inhibition (HI) assays against the vaccine strain and a vaccine-heterologous strain (A/Vietnam/1194/2004) 21 days after the second dose. A control group (safety) received a licensed seasonal inactivated trivalent influenza vaccine (TIV). Reactogenicity was assessed for 7 days after each vaccination, and unsolicited adverse events were assessed for 182 days following vaccination in both study groups (NCT01730378). Results: AS03-H5N1 was immunogenic and elicited robust HI antibody responses with seroconversion rates of 100% for the vaccine strain and 69.1% for the heterologous strain (. N=. 81). HI antibody responses fulfilled the European licensure criteria for immunogenicity (primary endpoint). The incidence of local and systemic solicited adverse events (reactogenicity) was higher with AS03-H5N1 than TIV. There was no apparent difference in the rate of unsolicited adverse events in the AS03-H5N1 and TIV groups. Conclusion: The results indicate that AS03-H5N1 vaccine is immunogenic with reactogenicity and safety findings that are consistent with the established profile of AS03-H5N1 vaccine.

Original languageEnglish
Pages (from-to)2800-2807
Number of pages8
JournalVaccine
Volume33
Issue number24
DOIs
Publication statusPublished - 2015 Jun 4

Fingerprint

Influenza Vaccines
Pandemics
pandemic
influenza
Vaccines
immune response
vaccines
Safety
Hemagglutination
Antibody Formation
Vaccination
Northern Asia
Indonesia
hemagglutination
Vietnam
Hemagglutinins
Licensure
North America
antibodies
vaccination

Keywords

  • AS03
  • H5N1 vaccine
  • Korean adults
  • Pandemic influenza

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults : A phase IV, randomized, open-label, controlled study. / Izurieta, Patricia; Kim, Woo Joo; Wie, Seong Heon; Lee, Jacob; Lee, Jin Soo; Dramé, Mamadou; Vaughn, David W.; Schuind, Anne.

In: Vaccine, Vol. 33, No. 24, 04.06.2015, p. 2800-2807.

Research output: Contribution to journalArticle

Izurieta, Patricia ; Kim, Woo Joo ; Wie, Seong Heon ; Lee, Jacob ; Lee, Jin Soo ; Dramé, Mamadou ; Vaughn, David W. ; Schuind, Anne. / Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults : A phase IV, randomized, open-label, controlled study. In: Vaccine. 2015 ; Vol. 33, No. 24. pp. 2800-2807.
@article{53b1228cb215498183cd00c4ead57d53,
title = "Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: A phase IV, randomized, open-label, controlled study",
abstract = "Background: AS03-adjuvanted H5N1 pandemic influenza vaccines have been assessed in an extensive clinical development program conducted in North America, Europe, and Asia including children from 6 months of age, adults, and elderly adults. We evaluated AS03-H5N1 in Korean adults 18 through 60 years of age. Methods: This Phase IV, randomized, study was conducted to assess the immunogenicity, reactogenicity, and safety of two doses (3.75. μg of hemagglutinin antigen) of A/Indonesia/5/2005 (H5N1) adjuvanted with AS03 given 21 days apart in Korean adults. Antibody responses were assessed using hemagglutination-inhibition (HI) assays against the vaccine strain and a vaccine-heterologous strain (A/Vietnam/1194/2004) 21 days after the second dose. A control group (safety) received a licensed seasonal inactivated trivalent influenza vaccine (TIV). Reactogenicity was assessed for 7 days after each vaccination, and unsolicited adverse events were assessed for 182 days following vaccination in both study groups (NCT01730378). Results: AS03-H5N1 was immunogenic and elicited robust HI antibody responses with seroconversion rates of 100{\%} for the vaccine strain and 69.1{\%} for the heterologous strain (. N=. 81). HI antibody responses fulfilled the European licensure criteria for immunogenicity (primary endpoint). The incidence of local and systemic solicited adverse events (reactogenicity) was higher with AS03-H5N1 than TIV. There was no apparent difference in the rate of unsolicited adverse events in the AS03-H5N1 and TIV groups. Conclusion: The results indicate that AS03-H5N1 vaccine is immunogenic with reactogenicity and safety findings that are consistent with the established profile of AS03-H5N1 vaccine.",
keywords = "AS03, H5N1 vaccine, Korean adults, Pandemic influenza",
author = "Patricia Izurieta and Kim, {Woo Joo} and Wie, {Seong Heon} and Jacob Lee and Lee, {Jin Soo} and Mamadou Dram{\'e} and Vaughn, {David W.} and Anne Schuind",
year = "2015",
month = "6",
day = "4",
doi = "10.1016/j.vaccine.2015.04.027",
language = "English",
volume = "33",
pages = "2800--2807",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "24",

}

TY - JOUR

T1 - Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults

T2 - A phase IV, randomized, open-label, controlled study

AU - Izurieta, Patricia

AU - Kim, Woo Joo

AU - Wie, Seong Heon

AU - Lee, Jacob

AU - Lee, Jin Soo

AU - Dramé, Mamadou

AU - Vaughn, David W.

AU - Schuind, Anne

PY - 2015/6/4

Y1 - 2015/6/4

N2 - Background: AS03-adjuvanted H5N1 pandemic influenza vaccines have been assessed in an extensive clinical development program conducted in North America, Europe, and Asia including children from 6 months of age, adults, and elderly adults. We evaluated AS03-H5N1 in Korean adults 18 through 60 years of age. Methods: This Phase IV, randomized, study was conducted to assess the immunogenicity, reactogenicity, and safety of two doses (3.75. μg of hemagglutinin antigen) of A/Indonesia/5/2005 (H5N1) adjuvanted with AS03 given 21 days apart in Korean adults. Antibody responses were assessed using hemagglutination-inhibition (HI) assays against the vaccine strain and a vaccine-heterologous strain (A/Vietnam/1194/2004) 21 days after the second dose. A control group (safety) received a licensed seasonal inactivated trivalent influenza vaccine (TIV). Reactogenicity was assessed for 7 days after each vaccination, and unsolicited adverse events were assessed for 182 days following vaccination in both study groups (NCT01730378). Results: AS03-H5N1 was immunogenic and elicited robust HI antibody responses with seroconversion rates of 100% for the vaccine strain and 69.1% for the heterologous strain (. N=. 81). HI antibody responses fulfilled the European licensure criteria for immunogenicity (primary endpoint). The incidence of local and systemic solicited adverse events (reactogenicity) was higher with AS03-H5N1 than TIV. There was no apparent difference in the rate of unsolicited adverse events in the AS03-H5N1 and TIV groups. Conclusion: The results indicate that AS03-H5N1 vaccine is immunogenic with reactogenicity and safety findings that are consistent with the established profile of AS03-H5N1 vaccine.

AB - Background: AS03-adjuvanted H5N1 pandemic influenza vaccines have been assessed in an extensive clinical development program conducted in North America, Europe, and Asia including children from 6 months of age, adults, and elderly adults. We evaluated AS03-H5N1 in Korean adults 18 through 60 years of age. Methods: This Phase IV, randomized, study was conducted to assess the immunogenicity, reactogenicity, and safety of two doses (3.75. μg of hemagglutinin antigen) of A/Indonesia/5/2005 (H5N1) adjuvanted with AS03 given 21 days apart in Korean adults. Antibody responses were assessed using hemagglutination-inhibition (HI) assays against the vaccine strain and a vaccine-heterologous strain (A/Vietnam/1194/2004) 21 days after the second dose. A control group (safety) received a licensed seasonal inactivated trivalent influenza vaccine (TIV). Reactogenicity was assessed for 7 days after each vaccination, and unsolicited adverse events were assessed for 182 days following vaccination in both study groups (NCT01730378). Results: AS03-H5N1 was immunogenic and elicited robust HI antibody responses with seroconversion rates of 100% for the vaccine strain and 69.1% for the heterologous strain (. N=. 81). HI antibody responses fulfilled the European licensure criteria for immunogenicity (primary endpoint). The incidence of local and systemic solicited adverse events (reactogenicity) was higher with AS03-H5N1 than TIV. There was no apparent difference in the rate of unsolicited adverse events in the AS03-H5N1 and TIV groups. Conclusion: The results indicate that AS03-H5N1 vaccine is immunogenic with reactogenicity and safety findings that are consistent with the established profile of AS03-H5N1 vaccine.

KW - AS03

KW - H5N1 vaccine

KW - Korean adults

KW - Pandemic influenza

UR - http://www.scopus.com/inward/record.url?scp=84929262391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929262391&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2015.04.027

DO - 10.1016/j.vaccine.2015.04.027

M3 - Article

VL - 33

SP - 2800

EP - 2807

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 24

ER -